Home > Insider Trading > Filing (0001209191-19-044309)

Filing Details

Accession Number:: 0001209191-19-044309
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-08-02 17:19:36
Reporting Period:: 2019-07-18

Accepted Time:: 2019-08-02 17:19:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1087294	Cumberland Pharmaceuticals Inc	CPIX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1470015	R Gordon Bernard	2525 West End Ave. Suite 950 Nashville TN 37203		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-07-18	500	$5.69	52,602	No	4	S	Direct
Common Stock	Disposition	2019-07-19	104	$5.61	52,498	No	4	S	Direct
Common Stock	Disposition	2019-07-22	200	$5.63	52,298	No	4	S	Direct
Common Stock	Disposition	2019-07-24	900	$5.84	51,398	No	4	S	Direct
Common Stock	Disposition	2019-07-25	500	$5.85	50,898	No	4	S	Direct
Common Stock	Disposition	2019-07-26	500	$5.83	50,398	No	4	S	Direct
Common Stock	Disposition	2019-07-29	424	$5.84	49,974	No	4	S	Direct
Common Stock	Disposition	2019-07-30	644	$5.81	49,330	No	4	S	Direct
Common Stock	Disposition	2019-07-31	1,100	$5.91	48,230	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.62, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.69 to $5.69, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.61 to $5.62, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.64 to $5.62, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.89 to $5.76, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.85, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.80, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.89 to $5.83, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.83 to $5.80, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.92 to $5.90, inclusive.